A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer

Japanese Journal of Clinical Oncology

Volumn 29, Issue 6, 1999, Pages 285-290

  Narabayashi, Masaru ^a   Takeyama, Kunihiko ^a,h   Fukutomi, Takashi ^a   Tokuda, Yutaka ^b   Tajima, Tomoo ^b   Okumura, Akira ^b   Chou, Takaaki ^c   Sano, Muneaki ^c   Makino, Haruhiko ^c   Igarashi, Tadahiko ^d   Sasaki, Yasutsuna ^d   Imoto, Shigeru ^d   Ogura, Michinori ^e   Morishima, Yasuo ^e   Murai, Hiroshi ^e   Okamoto, Shinichiro ^f   Ikeda, Tadashi ^f   Kasai, Masaharu ^g   Yokozawa, Toshiya ^a,h   Tobinai, Kensei ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g SAPPORO HOKUYU HOSPITAL   (Japan)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Granulocyte colony stimulating factor; Lenograstim; Mobilization; Peripheral blood stem cell

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADJUVANT CHEMOTHERAPY; ADULT; APHERESIS; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CYTOLOGY; DOSE RESPONSE; FEMALE; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; MACROPHAGE; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; POSTOPERATIVE CARE; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD34; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; INJECTIONS, SUBCUTANEOUS; MACROPHAGES; MASTECTOMY; MIDDLE AGED; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 0033142463     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.6.285     Document Type: Article

References (29)

1. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Bone Marrow Transplant 1998;21:1-7.
2. Gratwohl A, Hermans J, Baldomero H. Blood and marrow transplantation activity in Europe 1995. Bone Marrow Transplant 1997;19:407-19.
3. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-4.
4. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, et al. Granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-5.
5. Kohno A, Takeyama K, Narabayashi M, Okamoto R, Adachi I, Tobinai K, et al. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant 1995;15:49-54.
6. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-7.
7. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709-19.
8. Pettengell R, Testa NG, Swindell R, Crowther D, Dexter TM. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993;82:2239-48.
9. Shimazaki C, Oku N, Ashihara E, Okawa K, Goto H, Inaba T, et al. Collection of peripheral blood stern cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant 1992;10:341-6.
10. Shimazaki C, Yamagata N, Tatsumi T, Hirata T, Oku N, Ashihara E, et al. Mobilization of peripheral blood progenitor cells by high-dose Ara-C, VP-16 and recombinant human granulocyte colony-stimulating factor: Factors affecting progenitor cell yields. Bone Marrow Transplant 1995;15:763-7.
11. Jones HM, Jones SA, Watts MJ, Khwaja A, Mills W, Fielding A, et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994;12:1693-702.
12. Olivieri A, Offidani M, Ciniero L, Poloni A, Masia MC, Salvi A, et al. Optimization of the yield of PBSC for autotransplantation mobilized by high-dose chemotherapy and G-CSF: proposal for a mathematical model. Bone Marrow Transplant 1994;14:273-8.
13. Schwella N, Beyer J, Schwaner I, Heuft HG, Rick O, Huhn D, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell tumor. J Clin Oncol 1996;14:1114-21.
14. Schwella N, Rick O, Meyer O, Loffel J, Schleicher J, Serke S, et al. Mobilization of peripheral blood progenitor cells by disease-specific chemotherapy in patients with soft tissue sarcoma. Bone Marrow Transplant 1998;21:863-8.
15. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
16. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-121.
17. Croockewit AJ, Bronchud MH, Aapro MS, Bargetzi MJ, Crown J, Gratwohl A, et al. A European perspective on haematopoietic growth factors in haemato-oncology: Report of an expert meeting of the EORTC. Eur J Cancer 1997;33:1732-46.
18. Linch DC, Watts MJ. Standard after PBSC mobilisation and collection. Ann Oncol 1996;7 (Suppl 2): 9-10.
19. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collection in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9.
20. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlatins with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-31.
21. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-55.
22. + content. Bone Marrow Transplant 1997;19:1103-10.
23. Hoeglund M, Smedmyr B, Simmonsson B, Totterman T, Bengtsson M. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996;18:19-27.
24. Haas R, Moele R, Fruehauf S, Goldschmidt H, Witt B, Flentje M, et al. Patients' characteristics associated with successful mobilising and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-94.
25. Mitterer M, Hirber J, Gentilini I, Prinoth O, Fabris P, Emmerich B, et al. Target value tailed (TVT) apheresis approach for blood progenitor cell collection after high-dose chemotherapy and rh-G-CSF. Bone Marrow Transplant 1996;18:611-7.
26. Armitage S, Hargreaves R, Samson D, Brennan M, Kanfer E, Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997;20:587-91.
27. + cell count reliably predicts autograft yield. Bone Marrow Transplant 1998;22:125-30.
28. + cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant 1996;17:509-15.
29. Tobinai K, Takeyama K, Kasai M, Kiyama Y, Ogura M, Kawano F, et al. A dose-finding study of lenograstim for PBSC mobilization during biweekly CHOP in patients with non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1997;16:194a (abstr364).